GLPwatch
GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.
J Clin Transl Endocrinol · 2024
Last updated 2026-09-22A review of studies found that two GLP-1 drugs, liraglutide and dulaglutide, may reduce binge eating episodes and related issues in people with binge eating disorder or bulimia nervosa. However, the studies were small and not placebo-controlled, so larger, high-quality trials are needed to confirm these effects and determine safe dosing.
AI summary of the abstract below.
| Journal | J Clin Transl Endocrinol, 2024 |
|---|---|
| Citations | 68 |
| Relative citation ratio | 14.64 |
| NIH percentile | 99 |
| Molecules | — |
| Conditions studied | Depression, Anxiety |
Abstract
OBJECTIVE: Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.
METHODS: Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.
RESULTS: Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.
CONCLUSION: Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.
Verbatim abstract via PubMed 38449772 ↗